SI2547679T1 - Derivati 2,3 dihidro-1H-inden-1-il-2,7-diazaspiro(3.6)nonana in njihova uporaba kot antagonisti ali inverzni agonisti grelinskega receptorja - Google Patents
Derivati 2,3 dihidro-1H-inden-1-il-2,7-diazaspiro(3.6)nonana in njihova uporaba kot antagonisti ali inverzni agonisti grelinskega receptorjaInfo
- Publication number
- SI2547679T1 SI2547679T1 SI201130664T SI201130664T SI2547679T1 SI 2547679 T1 SI2547679 T1 SI 2547679T1 SI 201130664 T SI201130664 T SI 201130664T SI 201130664 T SI201130664 T SI 201130664T SI 2547679 T1 SI2547679 T1 SI 2547679T1
- Authority
- SI
- Slovenia
- Prior art keywords
- diazaspiro
- inden
- antagonists
- dihydro
- inverse agonists
- Prior art date
Links
- 102000000393 Ghrelin Receptors Human genes 0.000 title 1
- 108010016122 Ghrelin Receptors Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical class CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4747—Quinolines; Isoquinolines spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31552210P | 2010-03-19 | 2010-03-19 | |
| US201161444401P | 2011-02-18 | 2011-02-18 | |
| EP11713083.1A EP2547679B1 (en) | 2010-03-19 | 2011-03-11 | 2,3 dihydro-1h-inden-1-yl-2,7-diazaspiro[3.6]nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor |
| PCT/IB2011/051035 WO2011114271A1 (en) | 2010-03-19 | 2011-03-11 | 2,3 dihydro-1h-inden-1-yl- 2,7-diazaspiro [3.6] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2547679T1 true SI2547679T1 (sl) | 2015-12-31 |
Family
ID=44647714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201130664T SI2547679T1 (sl) | 2010-03-19 | 2011-03-11 | Derivati 2,3 dihidro-1H-inden-1-il-2,7-diazaspiro(3.6)nonana in njihova uporaba kot antagonisti ali inverzni agonisti grelinskega receptorja |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US8609680B2 (https=) |
| EP (1) | EP2547679B1 (https=) |
| JP (1) | JP5496409B2 (https=) |
| KR (1) | KR101455917B1 (https=) |
| CN (1) | CN102939290B (https=) |
| AR (1) | AR080688A1 (https=) |
| AU (1) | AU2011228699B2 (https=) |
| BR (1) | BR112012023664B1 (https=) |
| CA (1) | CA2792234C (https=) |
| CY (1) | CY1118721T1 (https=) |
| DK (1) | DK2547679T3 (https=) |
| ES (1) | ES2557895T3 (https=) |
| HR (1) | HRP20151232T1 (https=) |
| HU (1) | HUE025774T2 (https=) |
| IL (1) | IL221952A (https=) |
| ME (1) | ME02330B (https=) |
| MX (1) | MX2012010772A (https=) |
| PH (1) | PH12012501800A1 (https=) |
| PL (1) | PL2547679T3 (https=) |
| PT (1) | PT2547679E (https=) |
| RS (1) | RS54383B1 (https=) |
| RU (1) | RU2524341C2 (https=) |
| SG (1) | SG183812A1 (https=) |
| SI (1) | SI2547679T1 (https=) |
| TW (1) | TWI410423B (https=) |
| WO (1) | WO2011114271A1 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014029577A2 (pt) * | 2012-06-04 | 2017-06-27 | Pfizer | uso de agonistas ou antagonistas inversos do receptor de grelina para tratamento de transtornos do sono |
| CN104364239B (zh) | 2012-06-13 | 2017-08-25 | 霍夫曼-拉罗奇有限公司 | 二氮杂螺环烷烃和氮杂螺环烷烃 |
| MX368615B (es) | 2012-09-25 | 2019-10-09 | Hoffmann La Roche | Derivados bicíclicos como inhibidores de la autotaxina (atx) que son inhibidores de la producción de ácido lisofosfatídico (lpa) y el uso de los mismos. |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| DK3074400T3 (en) | 2013-11-26 | 2018-01-15 | Hoffmann La Roche | Octahydro-cyclobuta [1,2-c; 3,4-c '] dipyrrole derivatives as autotaxin inhibitors |
| JP6574438B2 (ja) * | 2014-03-17 | 2019-09-11 | リマインド エヌヴイＲｅｍｙｎｄ Ｎｖ | ２，７−ジアザスピロ［３．５］ノナン化合物 |
| EA032357B1 (ru) | 2014-03-26 | 2019-05-31 | Ф. Хоффманн-Ля Рош Аг | Конденсированные [1,4]диазепиновые соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa) |
| CA2937616A1 (en) | 2014-03-26 | 2015-10-01 | F. Hoffmann-La Roche Ag | Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors |
| CN106749002A (zh) * | 2015-02-12 | 2017-05-31 | 佛山市赛维斯医药科技有限公司 | 一种含硝基喹啉结构的葡萄糖激酶活化剂及其用途 |
| MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
| CA2992889A1 (en) | 2015-09-04 | 2017-03-09 | F. Hoffmann-La Roche Ag | Phenoxymethyl derivatives |
| JP6876685B2 (ja) | 2015-09-24 | 2021-05-26 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ａｔｘ阻害剤としての二環式化合物 |
| AU2016328436B2 (en) | 2015-09-24 | 2020-05-14 | F. Hoffmann-La Roche Ag | New bicyclic compounds as dual ATX/CA inhibitors |
| BR112017026682A2 (pt) | 2015-09-24 | 2018-08-14 | Hoffmann La Roche | novos compostos bicíclicos como inibidores de dupla ação de atx/ca |
| WO2017050732A1 (en) | 2015-09-24 | 2017-03-30 | F. Hoffmann-La Roche Ag | Bicyclic compounds as atx inhibitors |
| KR102882225B1 (ko) | 2017-02-21 | 2025-11-07 | 엘지전자 주식회사 | 냉장고 |
| JP7090099B2 (ja) | 2017-03-16 | 2022-06-23 | エフ．ホフマン－ラ ロシュ アーゲー | Ａｔｘインヒビターとしての新規二環式化合物 |
| RU2019132254A (ru) | 2017-03-16 | 2021-04-16 | Ф. Хоффманн-Ля Рош Аг | Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca |
| US10919852B2 (en) | 2017-07-28 | 2021-02-16 | Chemocentryx, Inc. | Immunomodulator compounds |
| CN108588215A (zh) * | 2018-05-03 | 2018-09-28 | 成都中创清科医学检验所有限公司 | 一种用于检测家族性高胆固醇血症易感性相关的snp位点的引物及其检测方法 |
| CN109970631A (zh) * | 2019-03-26 | 2019-07-05 | 上海吉奉生物科技有限公司 | 一种5-碘-2-吡啶乙酸的合成方法 |
| TWI848092B (zh) | 2019-04-03 | 2024-07-11 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白調節劑 |
| CN111777559B (zh) * | 2019-04-23 | 2021-11-09 | 苏州大学 | 基于端炔制备多取代吡唑的方法 |
| CN110172062B (zh) * | 2019-06-21 | 2022-01-07 | 南京药石科技股份有限公司 | 一种单氟代螺环化合物的合成方法及其中间体 |
| CA3150162A1 (en) * | 2019-08-14 | 2021-02-18 | Vertex Pharmaceuticals Incorporated | Crystalline forms of cftr modulators |
| EP4225762A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| MX2023006186A (es) | 2020-11-27 | 2023-08-07 | Shenzhen Salubris Pharm Co Ltd | Derivado de benzimidazol y método de preparación del mismo y uso médico del mismo. |
| AU2021397294A1 (en) | 2020-12-10 | 2023-07-06 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| KR20220001745U (ko) | 2021-01-06 | 2022-07-13 | 성보라 | 자동차시트 후면 보호용 보조커버 |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3595B (en) | 1993-01-21 | 1995-12-27 | Schering Corp | Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents |
| CA2439152C (en) | 2001-02-28 | 2008-06-17 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| JP2005504091A (ja) | 2001-09-21 | 2005-02-10 | シェーリング コーポレイション | ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置 |
| CN1642599A (zh) | 2002-02-27 | 2005-07-20 | 辉瑞产品公司 | Acc抑制剂 |
| SE0302811D0 (sv) * | 2003-10-23 | 2003-10-23 | Astrazeneca Ab | Novel compounds |
| PL1753748T3 (pl) | 2004-05-12 | 2010-01-29 | Pfizer Prod Inc | Pochodne proliny i ich zastosowanie jako inhibitorów peptydazy dipeptylowej IV |
| AP2006003768A0 (en) | 2004-05-25 | 2006-10-31 | Pfizer Prod Inc | TetraazabenzoÄeÜazulene derivatives and analogs tehereof |
| PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
| GB0514018D0 (en) * | 2005-07-07 | 2005-08-17 | Ionix Pharmaceuticals Ltd | Chemical compounds |
| WO2007058322A1 (ja) | 2005-11-18 | 2007-05-24 | Ono Pharmaceutical Co., Ltd. | 塩基性基を含有する化合物およびその用途 |
| AU2006331770A1 (en) | 2005-12-21 | 2007-07-05 | Schering Corporation | Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and H3 receptor antagonist/inverse agonist |
| EP2010520B1 (en) | 2006-04-20 | 2012-09-12 | Pfizer Products Inc. | Heterobicyclic amides for the prevention and treatment of glucokinase-mediated diseases |
| CA2663503A1 (en) * | 2006-09-15 | 2008-03-20 | Schering Corporation | Azetidinone derivatives and methods of use thereof |
| CA2663500A1 (en) * | 2006-09-15 | 2008-03-20 | Schering Corporation | Spiro-condensed azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism |
| BRPI0721053A2 (pt) | 2006-11-29 | 2014-07-29 | Pfizer Prod Inc | INIBIDORES DE ESPIROCETONA ACETIL-CoA CARBOXILASE |
| US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
| JP5435592B2 (ja) | 2008-05-28 | 2014-03-05 | ファイザー・インク | ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤 |
| WO2009144555A1 (en) | 2008-05-28 | 2009-12-03 | Pfizer Inc. | Pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| JPWO2009154132A1 (ja) * | 2008-06-19 | 2011-12-01 | Ｍｓｄ株式会社 | スピロジアミン−ジアリールケトオキシム誘導体 |
| JP2011529483A (ja) | 2008-07-29 | 2011-12-08 | ファイザー・インク | フッ素化ヘテロアリール |
| AU2009286380B2 (en) | 2008-08-28 | 2011-09-15 | Pfizer Inc. | Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives |
| TW201038580A (en) | 2009-02-02 | 2010-11-01 | Pfizer | 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives |
| EP2604604A1 (en) | 2009-03-11 | 2013-06-19 | Pfizer Inc | Benzofuranyl derivatives used as glucokinase inhibitors |
| CA2754685A1 (en) | 2009-03-11 | 2010-09-16 | Pfizer Inc. | Substituted indazole amides |
| WO2010106457A2 (en) | 2009-03-20 | 2010-09-23 | Pfizer Inc. | 3-oxa-7-azabicyclo[3.3.1]nonanes |
| TW201038572A (en) * | 2009-03-25 | 2010-11-01 | Gruenenthal Gmbh | Substituted spiro-amide compounds |
| US20120052130A1 (en) | 2009-05-08 | 2012-03-01 | Pfizer Inc. | Gpr 119 modulators |
| CA2759843A1 (en) | 2009-05-08 | 2010-11-10 | Pfizer Inc. | Gpr 119 modulators |
| NZ596467A (en) | 2009-06-05 | 2014-01-31 | Pfizer | L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators |
| US20120083476A1 (en) * | 2009-06-05 | 2012-04-05 | Janssen Pharmaceutica Nv | Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase |
| WO2011005611A1 (en) | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Neuromedin u receptor agonists and uses thereof |
-
2011
- 2011-03-11 DK DK11713083.1T patent/DK2547679T3/en active
- 2011-03-11 KR KR1020127027230A patent/KR101455917B1/ko not_active Expired - Fee Related
- 2011-03-11 PL PL11713083T patent/PL2547679T3/pl unknown
- 2011-03-11 SG SG2012062667A patent/SG183812A1/en unknown
- 2011-03-11 CN CN201180014627.7A patent/CN102939290B/zh not_active Expired - Fee Related
- 2011-03-11 AU AU2011228699A patent/AU2011228699B2/en not_active Ceased
- 2011-03-11 PH PH1/2012/501800A patent/PH12012501800A1/en unknown
- 2011-03-11 JP JP2013500620A patent/JP5496409B2/ja not_active Expired - Fee Related
- 2011-03-11 SI SI201130664T patent/SI2547679T1/sl unknown
- 2011-03-11 HR HRP20151232TT patent/HRP20151232T1/hr unknown
- 2011-03-11 MX MX2012010772A patent/MX2012010772A/es active IP Right Grant
- 2011-03-11 CA CA2792234A patent/CA2792234C/en not_active Expired - Fee Related
- 2011-03-11 BR BR112012023664A patent/BR112012023664B1/pt not_active IP Right Cessation
- 2011-03-11 HU HUE11713083A patent/HUE025774T2/en unknown
- 2011-03-11 PT PT117130831T patent/PT2547679E/pt unknown
- 2011-03-11 ES ES11713083.1T patent/ES2557895T3/es active Active
- 2011-03-11 RS RS20150808A patent/RS54383B1/sr unknown
- 2011-03-11 RU RU2012137489/04A patent/RU2524341C2/ru not_active IP Right Cessation
- 2011-03-11 ME MEP-2015-189A patent/ME02330B/me unknown
- 2011-03-11 EP EP11713083.1A patent/EP2547679B1/en active Active
- 2011-03-11 WO PCT/IB2011/051035 patent/WO2011114271A1/en not_active Ceased
- 2011-03-16 US US13/049,225 patent/US8609680B2/en active Active
- 2011-03-16 TW TW100109022A patent/TWI410423B/zh not_active IP Right Cessation
- 2011-03-18 AR ARP110100888A patent/AR080688A1/es not_active Application Discontinuation
-
2012
- 2012-09-13 IL IL221952A patent/IL221952A/en not_active IP Right Cessation
-
2013
- 2013-11-18 US US14/083,275 patent/US20140080756A1/en not_active Abandoned
-
2015
- 2015-12-04 CY CY20151101105T patent/CY1118721T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2547679T1 (sl) | Derivati 2,3 dihidro-1H-inden-1-il-2,7-diazaspiro(3.6)nonana in njihova uporaba kot antagonisti ali inverzni agonisti grelinskega receptorja | |
| ZA201105323B (en) | Agonists and antagonists of the sip5 receptor,and methods of uses thereof | |
| AP2012006276A0 (en) | New CCR2 receptor antagonists and uses thereof. | |
| ZA201202906B (en) | Novel naphthyridine derivatives and the use thereof as kinase inhibitors | |
| PL2627649T3 (pl) | Antagoniści receptora CXCR4 | |
| ZA201207259B (en) | 4-aminopyrimidine derivatives and their as as adenosine 121 receptor antagonists | |
| IL232382A0 (en) | History of fused pyrimidines, preparations containing them, and their uses | |
| IL218938A0 (en) | Salts, solvates, and pharmaceutical compositions of macrocyclic ghrelin receptor agonists and methods of using the same | |
| AP2010005363A0 (en) | Bridged, bicyclic heterocyclic or spiro bicyclic heterocyclic derivatives of pyrazoloÄ1,5-AÜ pyrimidines, methods for preparation and uses thereof. | |
| PL2651939T3 (pl) | Podstawione związki N-(1H-indazol-4-ylo)imidazo[1,2-a]pirydyno-3-karboksyamidu jako inhibitory receptorowych kinaz tyrozynowych typu III | |
| MY160665A (en) | Spiropiperidine compounds as orl-1 receptor antagonists | |
| PL2238110T3 (pl) | Pochodne 5,6-bisarylo-2-pirydyno-karboksamidu, ich wytwarzanie i ich zastosowanie terapeutyczne jako antagonistów receptora Urotensyny II | |
| IL205608A0 (en) | Triazole -substituted arylamide derivatives and their use as p2x3 and/or p2x2/3purinergic receptor antagonists | |
| AP2012006204A0 (en) | Indazole and pyrazolopyridine compounds as CCR1 receptor antagonists. | |
| IL216827A0 (en) | Benzyl substituted triazine derivatives, compositions comprising the same and uses thereof | |
| IL201012A0 (en) | Quinoline derivatives as crth2 receptor ligands | |
| IL225299A0 (en) | 7-Hydroxy-pyrazolo[1,5-a]pyrimidine compounds and their use as ccr2 receptor antagonists | |
| IL200380A0 (en) | Mineralcorticoid receptor antagonists for the treatment of endometriosis | |
| AU2011345414A1 (en) | Substituted methyl amines, serotonin 5-HT6 receptor antagonists, methods for the production and use thereof | |
| EP2657225A4 (en) | SUBSTITUTED METHYL AMINES, 5-HT6 SEROTONIN RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING | |
| SI3625221T1 (sl) | Derivati 3-metil-pirolidin-2,5-diona uporabni kot antagonisti CGRP receptorja | |
| IL212170A (en) | Mineral corticoid receptor antagonists, their atrophy isomers, their medicinal preparations and their use | |
| IL185640A0 (en) | Use of 2-anilino-3 ,4-dihydro-quinazolines as 5ht5a receptor antagonists | |
| IL235215A0 (en) | The l-malate salt of 7,2-diaza-spiro [4.5]7-dec yla, its derivatives and crystalline forms as ghrelin receptor agonists | |
| EP2351756A4 (en) | SUBSTITUTED 3-ARYLSULFONYL-PYRAZOLO [1,5-A] PYRIMIDINES, SEROTONIN-5-HT6 RECEPTOR ANTAGONISTS, AND METHOD FOR THEIR PREPARATION AND USE |